Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
9.68
Nov 11 • 3:59 PM ET Dollar change+0.42 Percentage change(4.54%)
Aftermarket Close
9.82
Aftermarket • 5:07 PM ET Dollar change+0.14 Percentage change(1.45%)
Nov 10, 11:23 AMHarvard Bioscience Q3 revenue rises 8% to $22.2M as company cuts FY26 adjusted EBITDA growth outlook on lower‑margin mix
Index
-
Market Cap
44.06M
Enterprise Value
83.49M
Income
-11.80M
Sales
89.41M
Book/sh
1.12
Cash/sh
1.07
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
339
IPO
Dec 07, 2000
P/E
-
Forward P/E
-
PEG
-
P/S
0.49
P/B
8.67
P/C
9.07
P/FCF
-
EV/EBITDA
17.18
EV/Sales
0.93
Quick Ratio
0.86
Current Ratio
1.76
Debt/Eq
8.67
LT Debt/Eq
8.33
Option/Short
No / Yes
EPS (ttm)
-2.62
EPS next Y
-0.03
EPS next Q
-0.00
EPS this Y
-408.33%
EPS next Y
97.05%
EPS next 5Y
-
EPS past 3/5Y
-77.14% -44.59%
Sales past 3/5Y
-8.60% -3.25%
EPS Y/Y TTM
78.52%
Sales Y/Y TTM
2.34%
EPS Q/Q
-108.14%
Sales Q/Q
7.79%
Insider Own
7.15%
Insider Trans
0.00%
Inst Own
41.81%
Inst Trans
2.88%
ROA
-15.40%
ROE
-123.13%
ROIC
-24.75%
Gross Margin
54.24%
Oper. Margin
-0.18%
Profit Margin
-13.20%
SMA20
12.95%
SMA50
16.73%
SMA200
47.68%
Trades
Shs Outstand
4.57M
Shs Float
4.23M
52W High
9.60 0.83%
52W Low
4.00 142.00%
Volatility
9.63% 5.28%
ATR (14)
0.48
RSI (14)
72.85
Beta
1.45
Rel Volume
4.90
Avg Volume
21.50K
Volume
105,448
Perf Week
12.43%
Perf Month
17.05%
Perf Quarter
45.13%
Perf Half Y
73.94%
Perf YTD
44.74%
Perf Year
59.34%
Perf 3Y
-75.80%
Perf 5Y
-87.49%
Perf 10Y
-62.77%
Prev Close
9.26
Price
9.68
Change %
4.54%
Consensus
Hold
Avg. Price Target
$10.25
Implied Upside
+5.9%
Analysts6incl. previous ratings
Rating Distribution3 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
TodayDowngrade
SStoneX
Speculative Buy → Hold
Apr 09, 2025Downgrade
KEY logoKKeyBanc Capital Markets
Overweight → Sector Weight
Mar 10, 2023Upgrade
TThe Benchmark Company
Speculative Buy → Buy$3 → $4-58.7%
Jan 07, 2021Upgrade
TThe Benchmark Company
Speculative Buy → Buy
Dec 09, 2020Initiated
NNorthland Capital
Outperform$6-38.0%
Nov 10, 2020Initiated
KEY logoKKeyBanc Capital Markets
Overweight$6-38.0%
Jul 08, 2019Downgrade
JJanney
Buy → Neutral$2-79.3%
Jan 24, 2018Reiterated
JJanney
Buy$5 → $8-17.4%
Jan 23, 2018Reiterated
TThe Benchmark Company
Buy$6 → $10+3.3%
Nov 17, 2016Initiated
SSingular Research
Buy$5.50-43.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Frost Mark TChief Financial OfficerMar 16 '26Buy5.005,00025,00017,500Apr 01 09:44 AM
DENELSKY STEPHEN JDirectorMar 17 '26Buy4.8710,00048,70021,000Mar 18 02:13 PM
Snider WilliamDirectorMar 16 '26Buy4.9912,52562,50023,525Mar 18 07:31 AM
Snider WilliamDirectorMar 17 '26Buy4.858,47541,10432,000Mar 18 07:31 AM
Duke John DChief Executive OfficerMar 16 '26Buy5.015,00025,050105,000Mar 17 05:56 PM
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, China, United Kingdom, and Rest of the World. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.
PresidentMr. John Duke
CFOMr. Mark T. Frost
Vice President of Global People OperationsMs. Lori Packer
Senior Vice President of CommercialMr. David Panzarella
Corporate ControllerKathryn Flynn